Data as of:
Price 01-14-26 16:00 ET,
Balance Sheet 2025-08-31,
Income Statement 2025-08-31,
Cash Flow 2025-08-31
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
12-21-2025
Income indicators
Value
Date
EBITDA Positive
No
12-21-2025
Net Income Positive
Yes
12-21-2025
Avg CA Burn (Annual %)
-13.59%
12-21-2025
Avg CA Burn (Quarterly %)
-0.95%
12-21-2025
Shares Outstanding Changes
Date
Shares Outstanding
Delta
No recent share changes
Interesting Volume Days
Date
Volume
Shares Outstanding
Volume / Shares
Price
No interesting volume events
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the Helicobacter pylori bacteria. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.